Please login to the form below

Not currently logged in
Email:
Password:

Merck acquires full control of ridaforolimus

Merck has restructured its agreement with ARIAD, acquiring full control of the development and commercialisation of ridaforolimus

Merck has restructured its agreement with ARIAD Pharmaceuticals, making it into an exclusive license agreement. This gives Merck full control of the development and global commercialisation of ridaforolimus - an investigational orally available mTOR inhibitor currently being evaluated for the treatment of multiple cancer types.

The deal involved an upfront payment to ARIAD of $50m, with agreed further milestone payments subject to regulatory filings and approvals of ridaforolimus in multiple cancer indications and the achievement of significant sales thresholds.

ARIAD will receive royalties on global net sales of ridaforolimus in lieu of a previously agreed profit split on US sales.

Merck will take over responsibility for all activities and has acquired decision rights on matters relating to the development, manufacturing and commercialisation of ridaforolimus.

The Investigational New Drug (IND) application will be transferred to Merck, who will file the marketing application worldwide for any oncology indications and lead all interactions with regulatory agencies.

"This amended agreement positions Merck and ARIAD to maximise the therapeutic potential of ridaforolimus by evaluating its properties in multiple cancer types and furthers Merck's commitment to oncology research and advancing the health of people suffering from cancer," said Muna Bhanji, senior vice president and general manager, Oncology franchise at Merck.


Merck wins second Fosamax trial

In a separate statement, Merck announced that a New York federal jury has unanimously ruled in the company's favour, rejecting claims from a plaintiff that Fosamax (alendrionate) had caused dental and jaw-related problems.

This is the second case involving dental and jaw-related problems alleged to be caused by Fosamax to go to trial. In September 2009, a US district court judge declared a mistrial in the first Fosamax case after jurors failed to reach a unanimous verdict. This case is to be retried in June 2010.

According to Merck, as of December 31, 2009, around 978 cases, which include approximately 1,356 plaintiff groups, had been filed and were pending against Merck in either federal or state court.

6th May 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...

Infographics